Metabolic medicines
Survodutide
A dual glucagon/GLP-1 agonist studied in obesity; the analysis method materially changes how results should be compared.
Human clinical research
Also known as: BI 456906
Practical use
Applying the explained evidence
- Where it fits
- A dual glucagon/GLP-1 agonist studied in obesity; the analysis method materially changes how results should be compared.
- Put the information into practice
- Compare like-for-like endpoints, duration and analysis methods before comparing trial headlines.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- The treatment-regimen analysis incorporates discontinuation and other treatment changes. It should not be ranked directly against another trial’s estimate assuming uninterrupted adherence.
Overview
Survodutide engages glucagon and GLP-1 receptors. SYNCHRONIZE-1 tested two active-treatment groups against placebo, with lifestyle counseling in all groups.
Risks and limitations
Gastrointestinal symptoms occurred in 80.9% and 89.7% of the active groups versus 47.9% with placebo. They were generally mild or moderate. No deaths were reported in this trial; that does not prove zero mortality risk.
How to read this
Compare like-for-like endpoints, duration and analysis methods before comparing trial headlines.
Research explained
SYNCHRONIZE-1: 76-week phase III results
Who was studied
725 adults with obesity or qualifying overweight, excluding diabetes; randomized double-blind placebo-controlled trial.
- First active group: weight change
- -12.2 %
- Second active group: weight change
- -13 %
- Placebo: weight change
- -5.4 %
What was found
Mean weight changes were −12.2% and −13.0% in the active groups versus −5.4% with placebo. At least 5% weight reduction occurred in 72.6%, 71.9% and 46.3%, respectively.
What it cannot establish
The treatment-regimen analysis incorporates discontinuation and other treatment changes. It should not be ranked directly against another trial’s estimate assuming uninterrupted adherence.
Read the original studySources
SYNCHRONIZE-1: 76-week phase III results
Sources checked 2026-09-28.
General education; not a personal treatment plan.